Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ATP2C1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ATP2C1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ATP2C1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ATP2C1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ATP2C1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ATP2C1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ATP2C1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ATP2C1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ATP2C1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ATP2C1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00068923 | Colorectum | FAP | post-Golgi vesicle-mediated transport | 36/2622 | 104/18723 | 9.23e-08 | 6.22e-06 | 36 |
GO:00988763 | Colorectum | FAP | vesicle-mediated transport to the plasma membrane | 42/2622 | 136/18723 | 3.16e-07 | 1.78e-05 | 42 |
GO:00619513 | Colorectum | FAP | establishment of protein localization to plasma membrane | 24/2622 | 60/18723 | 6.30e-07 | 3.09e-05 | 24 |
GO:00315323 | Colorectum | FAP | actin cytoskeleton reorganization | 34/2622 | 107/18723 | 1.99e-06 | 8.03e-05 | 34 |
GO:19043773 | Colorectum | FAP | positive regulation of protein localization to cell periphery | 25/2622 | 69/18723 | 3.21e-06 | 1.17e-04 | 25 |
GO:19030783 | Colorectum | FAP | positive regulation of protein localization to plasma membrane | 23/2622 | 62/18723 | 4.96e-06 | 1.61e-04 | 23 |
GO:00068932 | Colorectum | FAP | Golgi to plasma membrane transport | 22/2622 | 60/18723 | 9.86e-06 | 2.87e-04 | 22 |
GO:00430013 | Colorectum | FAP | Golgi to plasma membrane protein transport | 16/2622 | 40/18723 | 4.64e-05 | 9.57e-04 | 16 |
GO:00431222 | Colorectum | FAP | regulation of I-kappaB kinase/NF-kappaB signaling | 56/2622 | 249/18723 | 1.82e-04 | 2.69e-03 | 56 |
GO:00085441 | Colorectum | FAP | epidermis development | 66/2622 | 324/18723 | 9.63e-04 | 9.51e-03 | 66 |
GO:00431232 | Colorectum | FAP | positive regulation of I-kappaB kinase/NF-kappaB signaling | 42/2622 | 186/18723 | 1.01e-03 | 9.89e-03 | 42 |
GO:00072492 | Colorectum | FAP | I-kappaB kinase/NF-kappaB signaling | 58/2622 | 281/18723 | 1.37e-03 | 1.24e-02 | 58 |
GO:0042996 | Colorectum | FAP | regulation of Golgi to plasma membrane protein transport | 5/2622 | 10/18723 | 7.32e-03 | 4.38e-02 | 5 |
GO:00714211 | Colorectum | FAP | manganese ion transmembrane transport | 5/2622 | 10/18723 | 7.32e-03 | 4.38e-02 | 5 |
GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
GO:1903829111 | Esophagus | ESCC | positive regulation of cellular protein localization | 199/8552 | 276/18723 | 2.99e-19 | 3.45e-17 | 199 |
GO:1904951111 | Esophagus | ESCC | positive regulation of establishment of protein localization | 216/8552 | 319/18723 | 1.01e-15 | 6.86e-14 | 216 |
GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
GO:0051222111 | Esophagus | ESCC | positive regulation of protein transport | 204/8552 | 303/18723 | 1.56e-14 | 8.38e-13 | 204 |
GO:0072659110 | Esophagus | ESCC | protein localization to plasma membrane | 193/8552 | 284/18723 | 1.95e-14 | 1.03e-12 | 193 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP2C1 | SNV | Missense_Mutation | | c.514N>C | p.Glu172Gln | p.E172Q | P98194 | protein_coding | tolerated(0.17) | benign(0.037) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP2C1 | SNV | Missense_Mutation | | c.2170N>A | p.Glu724Lys | p.E724K | P98194 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP2C1 | SNV | Missense_Mutation | | c.359N>C | p.Leu120Pro | p.L120P | P98194 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ATP2C1 | SNV | Missense_Mutation | | c.1271G>C | p.Gly424Ala | p.G424A | P98194 | protein_coding | tolerated(0.3) | benign(0.406) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ATP2C1 | SNV | Missense_Mutation | | c.1339N>C | p.Asp447His | p.D447H | P98194 | protein_coding | deleterious(0.01) | possibly_damaging(0.81) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
ATP2C1 | SNV | Missense_Mutation | rs145949576 | c.1994C>T | p.Ser665Leu | p.S665L | P98194 | protein_coding | deleterious(0) | possibly_damaging(0.611) | TCGA-EW-A6SA-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ATP2C1 | insertion | Nonsense_Mutation | novel | c.195_196insTAGAATAAT | p.Val65_Ser66insTer | p.V65_S66ins* | P98194 | protein_coding | | | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
ATP2C1 | deletion | Frame_Shift_Del | | c.685delT | p.Cys229ValfsTer4 | p.C229Vfs*4 | P98194 | protein_coding | | | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP2C1 | deletion | Frame_Shift_Del | | c.340delN | p.Asn115IlefsTer16 | p.N115Ifs*16 | P98194 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ATP2C1 | SNV | Missense_Mutation | novel | c.2336C>T | p.Pro779Leu | p.P779L | P98194 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | ENFLURANE | ENFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | ISOFLURANE | ISOFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | SEVOFLURANE | SEVOFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | ISOFLURANE | ISOFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | ENFLURANE | ENFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | SEVOFLURANE | SEVOFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | DESFLURANE | DESFLURANE | |
27032 | ATP2C1 | ENZYME, TRANSPORTER, DRUGGABLE GENOME | | DESFLURANE | DESFLURANE | |